Inhibition of HIV/SIV replication by dominant negative Gag mutants.
There are several major strategies against HIV/AIDS. Of these, the gene therapy is a novel, challenging, and promising one. The target genes, which have been extensively studied for the potential gene therapy of HIV/AIDS, include those of cellular and viral origins. Especially, trans-dominant negative Tat, Rev, Env, Pol, and Gag mutants of HIV have currently attracted considerable attention. In this brief review, we summarize the nature of the HIV/SIV mutants of this category and discuss their future use for gene therapy with special reference to the dominant negative Gag mutants of HIV-1.
Shimano
R
R
Department of Virology, The University of Tokushima School of Medicine, Japan.
Inubushi
R
R
Oshima
Y
Y
Adachi
A
A
D005799:Genes, Dominant; D015750:Genes, gag; D015316:Genetic Therapy; D015658:HIV Infections / Q000628:therapy; D015497:HIV-1 / Q000235:genetics / Q000502:physiology*; D006801:Humans; D009154:Mutation; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000502:physiology*; D014779:Virus Replication / Q000235:genetics*